ArticlePloS one2024
Evaluating antibacterial and antioxidant properties of sericin recovered from cocoons of Bombyx mori, Gonometa postica and Samia ricini in Kenya.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bio-enhanced silk fibroin-based scaffolds for chronic diabetic foot ulcers.Burns & trauma · 2026Review
- Silk sericin and its biomedical applications: extraction methods, genetic insights (Ser1-Ser6), and developments of multifunctional biomaterials for tissue regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- Green synthesis of silver nanoparticles using cocoon extract of Bombyx mori L.: therapeutic potential in antibacterial, antioxidant, anti-inflammatory, and anti-tumor applications.BMC biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial infections and excessive reactive oxygen species are the primary contributors to delays in wound healing with Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus as the common wound infection causing bacteria. In fact, wound management has become more challenging since most of these microbes have developed resistance against commonly used conventional antibiotics thus making it necessary to develop natural products with both antibacterial and antioxidant activities. Increasing attention has been paid to silk sericin in the last decade, with limited research focus in Africa. Therefore, this work focus on evaluating antibacterial and antioxidant capacity of sericin recovered from cocoons of domesticated (Bombyx mori, Samia ricini) and wild (Gonometa postica) silkworms in Kenya. Sericin recovery was achieved using high temperature-high pressure method. Results revealed significance interspecies variation in all the parameters. Total flavonoid content ranged between 270±60.1 and 603.3±44.1 mg GAE/100g with S. ricini demonstrating the highest whereas G. postica exhibited the least content. Moreover, S. ricini showed the highest total phenolic content at 780.0±67.6 mg QE/100g while G. postica had the least phenolic content at 330.6±14.6 mg QE/100g. Samia ricini revealed the highest radical scavenging capacity at 40.47 ± 3.76% whereas B. mori sericin extract showed the least radical scavenging ability at 24.6± 2.96%. Furthermore, S. ricini silk sericin extract demonstrated the highest inhibitory activity against Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumonia which translated to 70.79 ± 11.28%, 93.86 ± 1.92%, 94.77 ± 7.07% when compared to streptomycin, chloramphenicol and oxytetracycline respectively. Bombyx mori and Gonometa postica showed the highest inhibitory activity against S. pyogene and E. coli respectively. These findings uncovered sufficient antibacterial efficacy of all three silk sericin extracts against both Gram-positive and negative bacteria, however, in depth research is still required to guarantee the aforementioned bioactivities to boost the therapeutic potential of silk sericin-based biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.